Content area

Abstract

The combination of next-generation sequencing and advanced computational data analysis approaches has revolutionized our understanding of the genomic underpinnings of cancer development and progression. The coincident development of targeted small molecule and antibody-based therapies that target a cancer’s genomic dependencies has fuelled the transition of genomic assays into clinical use in patients with cancer. Beyond the identification of individual targetable alterations, genomic methods can gauge mutational load, which might predict a therapeutic response to immune-checkpoint inhibitors or identify cancer-specific proteins that inform the design of personalized anticancer vaccines. Emerging clinical applications of cancer genomics include monitoring treatment responses and characterizing mechanisms of resistance. The increasing relevance of genomics to clinical cancer care also highlights several considerable challenges, including the need to promote equal access to genomic testing.

Alternate abstract:

Key points

Genomic assays that enable the characterization of the somatic and germline defects in individual tumour samples are increasingly being used in clinical diagnostics as a means of identifying therapeutic options.

Many technical and cost-associated considerations have a role in decision-making processes regarding the implementation of cancer genomics assays into clinical practice.

Genomic methods can reveal individual targetable alterations, mutational load, complex mutation signatures, and tumour-specific antigens, which might inform the utilization of targeted therapies, immune-checkpoint inhibitors, and personalized anticancer vaccines.

The occurrence of shared targetable alterations across diverse tumour types has prompted new paradigms in the application of genomic profiling and the design of clinical trials.

These assays increasingly provide information that is pertinent to clinical cancer care, although several important attendant challenges surround their implementation.

Details

Title
The emerging clinical relevance of genomics in cancer medicine
Author
Berger, Michael F 1 ; Mardis, Elaine R 2 

 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
 Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH, USA; Department of Pediatrics, Ohio State University College of Medicine, Columbus, OH, USA 
Pages
353-365
Publication year
2018
Publication date
Jun 2018
Publisher
Nature Publishing Group
ISSN
17594774
e-ISSN
17594782
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2041130492
Copyright
Copyright Nature Publishing Group Jun 2018